momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (6900)	4/10/2008 8:19:51 AM
From: Robohogs	Read Replies (1) of 12215

Jefferies notes that on Friday they held a conference call for clients featuring Amag Pharma (AMAG) CEO Dr. Brian Pereira. The firm says AMAG bears have argued that the ferumoxytol development program does not include a sufficient number of patient exposures to meet I.C.H safety guidelines (N=1,500). To set the record straight the firm notes, AMAG's CEO went on record (again) to confirm that, in total, over 1,700 patients and healthy volunteers were treated with ferumoxytol in the co's eleven clinical studies. The firm also says the fact that AMAG has the resources to execute additional clinical trials in C.K.D, but has chosen not to do so, suggests that AMAG strongly believes the filing is complete in its current form, per FDA guidance. Notablecalls: I do agree - at $38 the stock is a buy. seekingalpha.com Jon

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next